AACR22: Am­gen re­veals new long-term da­ta for Lumakras, look­ing to keep press­ing mar­ket ad­van­tage over Mi­rati

NEW OR­LEANS — Am­gen at­tempt­ed to fur­ther pull away from Mi­rati Ther­a­peu­tics in the KRAS space, tout­ing a new batch of long-term non-small cell lung can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.